High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers: Association with clinicopathological parameters

Nobuyuki Hakuma, Tomoko Betsuyaku, Ichiro Kinoshita, Tomoo Itoh, Kichizo Kaga, Satoshi Kondo, Masaharu Nishimura, Hirotoshi Dosaka-Akita

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: Extracellular matrix metalloproteinase inducer (EMMPRIN) is a highly glycosylated transmembrane protein that is widely present on the surface of various tumor cells, assisting in tumor progression by stimulating the production of several matrix metalloproteinases in adjacent stromal cells. However, its clinical relevance remains to be evaluated in lung cancers. Therefore, we aimed to investigate the relationship between EMMPRIN expression in non-small cell lung cancer (NSCLC) and clinicopathological characteristics and prognosis. Methods: EMMPRIN expression was semiquantified by immunohistochemistry with anti-human EMMPRIN monoclonal antibody in 208 surgically resected NSCLCs and was analyzed statistically in relation to various characteristics. Results: EMMPRIN expression was seen in most NSCLC samples (92%). High levels of EMMPRIN expression were significantly associated with differentiation and pT1 stage in adenocarcinomas. There were no significant differences in overall survival between patients with tumors having high and low levels of EMMPRIN expression in pathological stage I NSCLCs (5-year survival rates, 69 vs. 60%). Conclusions: EMMPRIN was preferentially expressed in most NSCLCs. High levels of expression were associated with early T stage and well-differentiated adenocarcinoma, and were not a prognostic factor in NSCLC.

Original languageEnglish
Pages (from-to)197-204
Number of pages8
JournalOncology
Volume72
Issue number3-4
DOIs
Publication statusPublished - 2008 Jan
Externally publishedYes

Fingerprint

CD147 Antigens
Non-Small Cell Lung Carcinoma
Incidence
Adenocarcinoma
Neoplasms
Stromal Cells
Matrix Metalloproteinases
Lung Neoplasms
Survival Rate
Immunohistochemistry
Monoclonal Antibodies

Keywords

  • Basigin
  • CD147
  • EMMPRIN
  • Immunohistochemistry
  • Lung cancer
  • Matrix metalloproteinases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers : Association with clinicopathological parameters. / Hakuma, Nobuyuki; Betsuyaku, Tomoko; Kinoshita, Ichiro; Itoh, Tomoo; Kaga, Kichizo; Kondo, Satoshi; Nishimura, Masaharu; Dosaka-Akita, Hirotoshi.

In: Oncology, Vol. 72, No. 3-4, 01.2008, p. 197-204.

Research output: Contribution to journalArticle

Hakuma, N, Betsuyaku, T, Kinoshita, I, Itoh, T, Kaga, K, Kondo, S, Nishimura, M & Dosaka-Akita, H 2008, 'High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers: Association with clinicopathological parameters', Oncology, vol. 72, no. 3-4, pp. 197-204. https://doi.org/10.1159/000112826
Hakuma, Nobuyuki ; Betsuyaku, Tomoko ; Kinoshita, Ichiro ; Itoh, Tomoo ; Kaga, Kichizo ; Kondo, Satoshi ; Nishimura, Masaharu ; Dosaka-Akita, Hirotoshi. / High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers : Association with clinicopathological parameters. In: Oncology. 2008 ; Vol. 72, No. 3-4. pp. 197-204.
@article{c97da913f48f4ac7816b301688549124,
title = "High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers: Association with clinicopathological parameters",
abstract = "Objective: Extracellular matrix metalloproteinase inducer (EMMPRIN) is a highly glycosylated transmembrane protein that is widely present on the surface of various tumor cells, assisting in tumor progression by stimulating the production of several matrix metalloproteinases in adjacent stromal cells. However, its clinical relevance remains to be evaluated in lung cancers. Therefore, we aimed to investigate the relationship between EMMPRIN expression in non-small cell lung cancer (NSCLC) and clinicopathological characteristics and prognosis. Methods: EMMPRIN expression was semiquantified by immunohistochemistry with anti-human EMMPRIN monoclonal antibody in 208 surgically resected NSCLCs and was analyzed statistically in relation to various characteristics. Results: EMMPRIN expression was seen in most NSCLC samples (92{\%}). High levels of EMMPRIN expression were significantly associated with differentiation and pT1 stage in adenocarcinomas. There were no significant differences in overall survival between patients with tumors having high and low levels of EMMPRIN expression in pathological stage I NSCLCs (5-year survival rates, 69 vs. 60{\%}). Conclusions: EMMPRIN was preferentially expressed in most NSCLCs. High levels of expression were associated with early T stage and well-differentiated adenocarcinoma, and were not a prognostic factor in NSCLC.",
keywords = "Basigin, CD147, EMMPRIN, Immunohistochemistry, Lung cancer, Matrix metalloproteinases",
author = "Nobuyuki Hakuma and Tomoko Betsuyaku and Ichiro Kinoshita and Tomoo Itoh and Kichizo Kaga and Satoshi Kondo and Masaharu Nishimura and Hirotoshi Dosaka-Akita",
year = "2008",
month = "1",
doi = "10.1159/000112826",
language = "English",
volume = "72",
pages = "197--204",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers

T2 - Association with clinicopathological parameters

AU - Hakuma, Nobuyuki

AU - Betsuyaku, Tomoko

AU - Kinoshita, Ichiro

AU - Itoh, Tomoo

AU - Kaga, Kichizo

AU - Kondo, Satoshi

AU - Nishimura, Masaharu

AU - Dosaka-Akita, Hirotoshi

PY - 2008/1

Y1 - 2008/1

N2 - Objective: Extracellular matrix metalloproteinase inducer (EMMPRIN) is a highly glycosylated transmembrane protein that is widely present on the surface of various tumor cells, assisting in tumor progression by stimulating the production of several matrix metalloproteinases in adjacent stromal cells. However, its clinical relevance remains to be evaluated in lung cancers. Therefore, we aimed to investigate the relationship between EMMPRIN expression in non-small cell lung cancer (NSCLC) and clinicopathological characteristics and prognosis. Methods: EMMPRIN expression was semiquantified by immunohistochemistry with anti-human EMMPRIN monoclonal antibody in 208 surgically resected NSCLCs and was analyzed statistically in relation to various characteristics. Results: EMMPRIN expression was seen in most NSCLC samples (92%). High levels of EMMPRIN expression were significantly associated with differentiation and pT1 stage in adenocarcinomas. There were no significant differences in overall survival between patients with tumors having high and low levels of EMMPRIN expression in pathological stage I NSCLCs (5-year survival rates, 69 vs. 60%). Conclusions: EMMPRIN was preferentially expressed in most NSCLCs. High levels of expression were associated with early T stage and well-differentiated adenocarcinoma, and were not a prognostic factor in NSCLC.

AB - Objective: Extracellular matrix metalloproteinase inducer (EMMPRIN) is a highly glycosylated transmembrane protein that is widely present on the surface of various tumor cells, assisting in tumor progression by stimulating the production of several matrix metalloproteinases in adjacent stromal cells. However, its clinical relevance remains to be evaluated in lung cancers. Therefore, we aimed to investigate the relationship between EMMPRIN expression in non-small cell lung cancer (NSCLC) and clinicopathological characteristics and prognosis. Methods: EMMPRIN expression was semiquantified by immunohistochemistry with anti-human EMMPRIN monoclonal antibody in 208 surgically resected NSCLCs and was analyzed statistically in relation to various characteristics. Results: EMMPRIN expression was seen in most NSCLC samples (92%). High levels of EMMPRIN expression were significantly associated with differentiation and pT1 stage in adenocarcinomas. There were no significant differences in overall survival between patients with tumors having high and low levels of EMMPRIN expression in pathological stage I NSCLCs (5-year survival rates, 69 vs. 60%). Conclusions: EMMPRIN was preferentially expressed in most NSCLCs. High levels of expression were associated with early T stage and well-differentiated adenocarcinoma, and were not a prognostic factor in NSCLC.

KW - Basigin

KW - CD147

KW - EMMPRIN

KW - Immunohistochemistry

KW - Lung cancer

KW - Matrix metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=38549181617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549181617&partnerID=8YFLogxK

U2 - 10.1159/000112826

DO - 10.1159/000112826

M3 - Article

C2 - 18160808

AN - SCOPUS:38549181617

VL - 72

SP - 197

EP - 204

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 3-4

ER -